BlackRock Inc. increased its stake in shares of Humana Inc (NYSE:HUM) by 1.2% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 12,311,736 shares of the insurance provider’s stock after acquiring an additional 140,731 shares during the quarter. BlackRock Inc. owned 0.09% of Humana worth $4,167,767,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Stratos Wealth Partners LTD. bought a new stake in Humana during the third quarter worth $108,000. Sun Life Financial INC grew its holdings in Humana by 120.7% during the second quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock worth $111,000 after buying an additional 204 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Humana by 2,984.6% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock worth $119,000 after buying an additional 388 shares in the last quarter. Smithfield Trust Co. grew its holdings in Humana by 531.2% during the third quarter. Smithfield Trust Co. now owns 486 shares of the insurance provider’s stock worth $165,000 after buying an additional 409 shares in the last quarter. Finally, Girard Partners LTD. bought a new stake in Humana during the third quarter worth $169,000. Institutional investors and hedge funds own 93.05% of the company’s stock.
In other news, insider Roy A. Beveridge sold 4,622 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the transaction, the insider now owns 10,621 shares of the company’s stock, valued at approximately $3,622,398.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce D. Broussard sold 18,000 shares of the company’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the transaction, the chief executive officer now directly owns 71,085 shares in the company, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. 0.60% of the stock is owned by corporate insiders.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.29 by $0.29. Humana had a return on equity of 19.10% and a net margin of 2.70%. The business had revenue of $14.21 billion for the quarter, compared to analysts’ expectations of $13.97 billion. During the same quarter in the previous year, the firm earned $3.39 earnings per share. As a group, research analysts predict that Humana Inc will post 14.43 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, December 28th. This represents a $2.00 annualized dividend and a yield of 0.66%. Humana’s dividend payout ratio is currently 17.08%.
Several equities research analysts recently issued reports on HUM shares. Argus upped their price target on Humana to $375.00 and gave the stock a “buy” rating in a report on Tuesday, September 4th. Piper Jaffray Companies reiterated a “buy” rating and set a $355.00 price target on shares of Humana in a report on Thursday, August 2nd. Bank of America upped their price target on Humana from $338.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Jefferies Financial Group upped their price target on Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a report on Thursday, August 2nd. Finally, Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $377.00 price objective on the stock in a research report on Thursday, October 4th. Seven research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $352.30.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Featured Article: What are the components of an earnings report?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.